期刊
ANTICANCER RESEARCH
卷 33, 期 5, 页码 1819-1827出版社
INT INST ANTICANCER RESEARCH
关键词
Artesunate; cancer; safety study; dog; comparative oncology
类别
资金
- Utrecht Faculty of Veterinary Medicine [DE 120053.2.02.1]
The anti-malarial drug artesunate has Mown anticancer activity in vitro and in preliminary animal experiments, but experience in patients with cancer is very limited. Pre-clinical studies in dogs indicated morbidity at high dosage levels. This study evaluated the effects of artesunate in canine cancer cell lines and in canine cancer patients. Four canine cell lines were tested in vitro for sensitivity towards artesunate and dihydroartemisinin (DHA; active metabolite of artesunate). The half-maximal inhibitory concentration (IC50) values for artesunate or DHA were 2-60 mu M in three cell lines, while one cell line was much less sensitive to artesunate (IC50 337 mu M) than to DHA (IC50 50 mu M). A safety/efficacy field study with artesunate was conducted in 23 dogs with non-resectable tumours. Artesunate was administered for 7-385 days at a dosage of 651-1178 (median 922) mg/m(2). No neurological or cardiac toxicity was observed and seven dogs exhibited no adverse effects at all. Fever and haematological/gastrointestinal toxicity, mostly transient, occurred in 16 dogs. One dog died from pneumonia. Plasma artesunate and DHA levels fell below the limit of detection within 8-12 h after artesunate administration, while levels after two hours were close to 1 mu M. Artesunate produced a long-lasting complete remission in one case of cancer and short-term stabilization of another seven cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据